Buy Rating Affirmed for SeaStar Medical on Strong Pediatric Milestone and AKI Market Opportunity
Maxim Group Maintains SeaStar Medical(ICU.US) With Buy Rating, Announces Target Price $18
Promising Clinical Trials and Strong Financial Positioning Bolster Buy Rating Recommendation for SeaStar Medical Holdings
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and SeaStar Medical Holding (ICU)
Analysts Conflicted on These Healthcare Names: Ibio (IBIO), SeaStar Medical Holding (ICU) and Viking Therapeutics (VKTX)
Maxim Group Initiates Coverage On SeaStar Medical Holding With Buy Rating, Announces Price Target of $5
No Data
No Data